Patients receiving chemotherapy have often complained of problems with memory, problem-solving and other cognitive abilities. Although chemotherapy was thought not to affect brain cells due to the blood-brain
The study will evaluate the safety, tolerability and pharmacokinetics of single escalating doses of A-831 in healthy volunteers in the UK. A-831 targets the NS5a protein and is
Net income fell 35% from the $22.3 billion acquisition of Schering, but exceeded analysts expectations. According to Bayer, the acquired Schering business contributed E1.4 billion to sales in
Under the terms of the agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek to obtain regulatory approvals in both China and Taiwan to launch
The inhibiting vascular adhesion protein-1 (VAP-1) reduces inflammation by regulating the migration of white blood cells to inflamed tissues. BioTie’s fully human VAP-1 antibody is based on Medarex’
The Economic Times reported that the company would not achieve its target through organic growth. The company would only be able to reach $2 billion in revenue through
The results of the study, carried out by experts from the University of Manchester, the University of Cambridge, Imperial College and the Institute of Psychiatry in London, found
In its ruling, the court approved agreements that created Protiva Biotherapeutics and the ongoing litigation with Protiva. The court rejected all motions raised by Protiva to block the
The FDA fast-tracks the new drug application process if a therapy can potentially address an unmet medical need for a life-threatening disease. Designation as a fast track product
“This is a major milestone in our strategy to advance our lead drug into a second indication,” said Kevin Giese, president of BioMS Medical. “MBP8298 has shown potential
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.